UnitedHealthcare coverage for Wegovy depends on employer, marketplace, or individual plan design, with many requiring prior authorization, BMI criteria, and documented medical necessity for approval
Tirzepatide creates the caloric deficit
animal research uses mg/kg Research protocols should reference published methodology for the specific research model
The development of GLP-1 receptor agonists for type 2 diabetes was contextualised within the broader research landscape, including orally bioavailable agonists, allosteric modulators, and unimolecular multi-agonists all of which use the native GLP-1 receptor as their primary target
Hi there, we had a similar question earlier for a different drug aimed at type 2 diabetes that also slows gut function